https://inovio.com/technology/publications/a-novel-prototype-device-for-electroporation-enhanced-dna-vaccine-delivery-simultaneously-to-both-skin-and-muscle/2026-07-29T22:38:52-04:00https://inovio.com/technology/publications/integration-of-needle-free-jet-injection-with-advanced-electroporation-delivery-enhances-the-magnitude-kinetics-and-persistence-of-engineered-dna-vaccine-induced-immune-responses/2026-07-29T22:38:52-04:00https://inovio.com/technology/publications/dna-encoded-bispecific-t-cell-engagers-and-antibodies-present-long-term-antitumor-activity/2026-07-29T22:38:52-04:00https://inovio.com/technology/publications/synthetic-nucleic-acid-antibody-prophylaxis-confers-rapid-and-durable-protective-immunity-against-zika-virus-challenge/2026-07-29T22:38:52-04:00https://inovio.com/technology/publications/in-vivo-delivery-of-a-dna-encoded-monoclonal-antibody-protects-non-human-primates-against-zika-virus/2026-07-29T22:38:52-04:00https://inovio.com/technology/publications/in-vivo-delivery-of-synthetic-human-dna-encoded-monoclonal-antibodies-protect-against-ebolavirus-infection-in-a-mouse-model/2026-07-29T22:38:52-04:00https://inovio.com/technology/publications/synthetic-dna-encoded-monoclonal-antibody-delivery-of-anti-ctla-4-antibodies-induces-tumor-shrinkage-in-vivo/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/novel-prostate-cancer-immunotherapy-with-a-dna-encoded-anti-prostate-specific-membrane-antigen-monoclonal-antibody/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/dmab-inoculation-of-synthetic-cross-reactive-antibodies-protects-against-lethal-influenza-a-and-b-infections/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/safety-efficacy-and-immunogenicity-of-vgx-3100-a-therapeutic-synthetic-dna-vaccine-targeting-human-papillomavirus-16-and-18-e6-and-e7-proteins-for-cervical-intraepithelial-neoplasia-2-3-a-randomis/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/immunotherapy-against-hpv16-18-generates-potent-th1-and-cytotoxic-cellular-immune-responses/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/augmentation-of-cellular-and-humoral-immune-responses-to-hpv16-and-hpv18-e6-and-e7-antigens-by-vgx-3100/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/clinical-and-immunologic-biomarkers-for-histologic-regression-of-high-grade-cervical-dysplasia-and-clearance-of-hpv16-and-hpv18-after-immunotherapy/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/adverse-obstetric-outcomes-after-local-treatment-for-cervical-preinvasive-and-early-invasive-disease-according-to-cone-depth-systematic-review-and-meta-analysis/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/immune-therapy-targeting-e6-e7-oncogenes-of-human-papillomavirus-type-6-hpv-6-reduces-or-eliminates-the-need-for-surgical-intervention-in-the-treatment-of-hpv-6-associated-recurrent-respiratory-papi/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/immunotherapy-targeting-hpv16-18-generates-potent-immune-responses-in-hpv-associated-head-and-neck-cancer/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/synergy-of-immune-checkpoint-blockade-with-a-novel-synthetic-consensus-dna-vaccine-targeting-tert/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/highly-optimized-dna-vaccine-targeting-human-telomerase-reverse-transcriptase-stimulates-potent-antitumor-immunity/2026-07-29T22:38:53-04:00https://inovio.com/technology/publications/a-novel-dna-vaccine-platform-enhances-neo-antigen-like-t-cell-responses-against-wt1-to-break-tolerance-and-induce-anti-tumor-immunity/2026-07-29T22:38:54-04:00https://inovio.com/technology/publications/cd8-t-cells-impact-rising-psa-in-biochemically-relapsed-cancer-patients-using-immunotherapy-targeting-tumor-associated-antigens/2026-07-29T22:38:54-04:00https://inovio.com/technology/publications/co-delivery-of-psa-and-psma-dna-vaccines-with-electroporation-induces-potent-immune-responses/2026-07-29T22:38:54-04:00https://inovio.com/technology/publications/synthetic-consensus-hiv-1-dna-induces-potent-cellular-immune-responses-and-synthesis-of-granzyme-b-perforin-in-hiv-infected-individuals/2026-07-29T22:38:54-04:00https://inovio.com/technology/publications/hiv-1-env-dna-vaccine-plus-protein-boost-delivered-by-ep-expands-b-and-t-cell-responses-and-neutralizing-phenotype-in-vivo/2026-07-29T22:38:54-04:00https://inovio.com/technology/publications/immunogenicity-of-a-novel-engineered-hiv-1-clade-c-synthetic-consensus-based-envelope-dna-vaccine/2026-07-29T22:38:54-04:00https://inovio.com/technology/publications/intradermal-syncon-ebola-gp-dna-vaccine-is-temperature-stable-and-safely-demonstrates-cellular-and-humoral-immunogenicity-advantages-in-healthy-volunteers/2026-07-29T22:38:54-04:00https://inovio.com/technology/publications/protective-efficacy-and-long-term-immunogenicity-in-cynomolgus-macaques-by-ebola-virus-glycoprotein-synthetic-dna-vaccines/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/rapid-response-to-an-emerging-infectious-disease-lessons-learned-from-development-of-a-synthetic-dna-vaccine-targeting-zika-virus/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/zika-induced-male-infertility-in-mice-is-potentially-reversible-and-preventable-by-deoxyribonucleic-acid-immunization/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/safety-and-immunogenicity-of-an-anti-zika-virus-dna-vaccine-preliminary-report/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/dna-vaccination-protects-mice-against-zika-virus-induced-damage-to-the-testes/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/in-vivo-protection-against-zikv-infection-and-pathogenesis-through-passive-antibody-transfer-and-active-immunisation-with-a-prmenv-dna-vaccine/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/safety-and-immunogenicity-of-an-anti-middle-east-respiratory-syndrome-coronavirus-dna-vaccine-a-phase-1-open-label-single-arm-dose-escalation-trial/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/a-synthetic-consensus-anti-spike-protein-dna-vaccine-induces-protective-immunity-against-middle-east-respiratory-syndrome-coronavirus-in-nonhuman-primates/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/broad-cross-protective-anti-hemagglutination-responses-elicited-by-influenza-microconsensus-dna-vaccine/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/an-engineered-bispecific-dna-encoded-igg-antibody-protects-against-pseudomonas-aeruginosa-in-a-pneumonia-challenge-model/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/rapid-and-long-term-immunity-elicited-by-dna-encoded-antibody-prophylaxis-and-dna-vaccination-against-chikungunya-virus/2026-07-29T22:38:55-04:00https://inovio.com/technology/publications/protection-against-dengue-disease-by-synthetic-nucleic-acid-antibody-prophylaxis-immunotherapy/2026-07-29T22:38:56-04:00https://inovio.com/technology/publications/ifnl3-adjuvanted-hcv-dna-vaccine-reduces-regulatory-t-cell-frequency-and-increases-virus-specific-t-cell-responses/2026-07-29T22:38:56-04:00https://inovio.com/technology/publications/immunogenicity-of-a-dna-vaccine-candidate-for-covid-19/2026-07-29T22:38:56-04:00https://inovio.com/technology/publications/571-safety-and-immunogenicity-of-ino-4800-a-covid-19-dna-vaccine-as-a-primary-series-and-booster/2026-07-29T22:38:56-04:00https://inovio.com/technology/publications/sars-cov-2-dna-vaccine-ino-4800-induces-durable-immune-responses-capable-of-being-boosted-in-a-phase-1-open-label-trial/2026-07-29T22:38:56-04:00https://inovio.com/technology/publications/ino-4800-dna-vaccine-induces-neutralizing-antibodies-and-t-cell-activity-against-global-sars-cov-2-variants/2026-07-29T22:38:56-04:00https://inovio.com/technology/publications/interim-results-of-a-phase-1-2-open-label-study-of-ino-3107-for-hpv-6-and-or-hpv-11-associated-recurrent-respiratory-papillomatosis/2026-07-29T22:38:57-04:00https://inovio.com/technology/publications/vaccines-for-hpv-associated-diseases/2026-07-29T22:38:57-04:00https://inovio.com/technology/publications/phase-i-trial-of-a-therapeutic-dna-vaccine-for-preventing-hepatocellular-carcinoma-from-chronic-hepatitis-c-virus-hcv-infection/2026-07-29T22:38:57-04:00https://inovio.com/technology/publications/intradermal-dna-vaccine-delivery-using-vacuum-controlled-needle-free-electroporation/2026-07-29T22:38:57-04:00https://inovio.com/technology/publications/delineation-of-dna-and-mrna-covid-19-vaccine-induced-immune-responses-in-preclinical-animal-models/2026-07-29T22:38:57-04:00https://inovio.com/technology/publications/multivalent-in-vivo-delivery-of-dna-encoded-bispecific-t-cell-engagers-effectively-controls-heterogeneous-gbm-tumors-and-mitigates-immune-escape/2026-07-29T22:38:57-04:00https://inovio.com/technology/publications/engineered-antibody-cytokine-chimera-synergizes-with-dna-launched-nanoparticle-vaccines-to-potentiate-melanoma-suppression-in-vivo/2026-07-29T22:38:57-04:00https://inovio.com/technology/publications/dna-immunotherapy-for-recurrent-respiratory-papillomatosis-rrp-phase-1-2-study-assessing-efficacy-safety-and-immunogenicity-of-ino-3107/2026-07-29T22:38:57-04:00https://inovio.com/technology/publications/safety-and-pharmacokinetics-of-sars-cov-2-dna-encoded-monoclonal-antibodies-in-healthy-adults-a-phase-1-trial/2026-07-29T22:38:57-04:00https://inovio.com/technology/publications/safety-tolerability-and-immunogenicity-of-ino-4500-a-synthetic-dna-based-vaccine-against-lassa-virus-in-a-phase-1b-clinical-trial-in-healthy-ghanaian-adults/2026-07-29T22:38:57-04:00https://inovio.com/technology/publications/safety-tolerability-and-immunogenicity-of-a-dna-based-vaccine-ino-4700-against-middle-east-respiratory-syndrome-coronavirus-phase-2a-study-in-healthy-volunteers/2026-07-29T22:38:58-04:00